Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer

被引:17
|
作者
Mendoza, Dexter P. [1 ]
Lin, Jessica J. [2 ,3 ]
Rooney, Marguerite M. [2 ,3 ]
Chen, Tianqi [4 ]
Sequist, Lecia V. [2 ,3 ]
Shaw, Alice T. [2 ,3 ]
Digumarthy, Subba R. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Founders 202, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[4] Harvard Med Sch, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
ALK; anaplastic lymphoma kinase; lung cancer; metastasis; FACTOR RECEPTOR MUTATION; EML4-ALK FUSION GENE; CLINICORADIOLOGIC CHARACTERISTICS; OPEN-LABEL; CRIZOTINIB; ADENOCARCINOMA; FISH; EGFR; GEFITINIB; ALECTINIB;
D O I
10.2214/AJR.19.21982
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. ALK rearrangements are an established targetable oncogenic driver in non-small cell lung cancer (NSCLC). The goal of this study was to determine the imaging features of the primary tumor and metastatic patterns in advanced ALK-rearranged (ALK+) NSCLC that may be different from those in EGFR-mutant (EGFR+) or EGFR/ALK wild-type (EGFR-/ALK-) NSCLC. MATERIALS AND METHODS. Patients with advanced ALK+, EGFR+, or EGFR-/ ALK- NSCLC were retrospectively identified. Two radiologists concurrently assessed the imaging features of the primary tumor and the distribution of metastases in these patients. RESULTS. We identified a cohort of 333 patients with metastatic NSCLC (119 ALK+ cases, 116 EGFR+ cases, and 98 EGFR-/ALK- cases). Compared with EGFR+ and EGFR-/ ALK- NSCLC, the primary tumor in ALK+ NSCLC was more likely to be located in the lower lobes (53% of ALK+, 34% of EGFR+, and 36% of EGFR-/ALK- tumors; p < 0.05), less likely to be subsolid (1% of ALK+, 11% of EGFR+, and 8% of EGFR-/ALK- tumors; p < 0.02), and less likely to have air bronchograms (7% of ALK+, 28% of EGFR+, and 29% of EGFR-TALK- tumors; p < 0.01). Compared with EGFR+ and EGFR-TALK- tumors, ALK+ tumors had higher frequencies of distant nodal metastasis (20% of ALK+ tumors vs 2% of EGFR+ and 9% of EGFR-/ALK- tumors; p < 0.05) and lymphangitic carcinomatosis (37% of ALK+ tumors vs 12% of EGFR+ and 12% of EGFR-/ALK- tumors; p < 0.01), but ALK+ tumors had a lower frequency of brain metastasis compared with EGFR+ tumors (24% vs 41%; p = 0.01). Although there was no statistically significant difference in the frequencies of bone metastasis among the three groups, sclerotic bone metastases were more common in the ALK+ tumors (22% vs 7% of EGFR+ tumors and 6% of EGFR-/ALK- tumors; p < 0.01). CONCLUSION. Advanced ALK+ NSCLC has primary tumor imaging features and patterns of metastasis that are different from those of EGFR+ or EGFR-ALK- wild type NSCLC at the time of initial presentation.
引用
收藏
页码:766 / 774
页数:9
相关论文
共 50 条
  • [41] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
    Shaw, Alice T.
    Engelman, Jeffrey A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2539
  • [42] Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?
    Chazan, G.
    Franchini, F.
    Shah, R.
    Alexander, M.
    John, A.
    IJzerman, M.
    Solomon, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S428 - S428
  • [43] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    [J]. CANCER SCIENCE, 2023, 114 : 830 - 830
  • [44] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    [J]. CANCER SCIENCE, 2023, 114 : 1474 - 1474
  • [45] Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
    Gandhi, Leena
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3737 - 3742
  • [46] Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
    Califano, Raffaele
    Greystoke, Alastair
    Lal, Rohit
    Thompson, Joyce
    Popat, Sanjay
    [J]. LUNG CANCER, 2017, 111 : 51 - 58
  • [47] Pretreatment Thoracic CT Radiomic Features to Predict Brain Metastases in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
    Wang, Hua
    Chen, Yong-Zi
    Li, Wan-Hu
    Han, Ying
    Li, Qi
    Ye, Zhaoxiang
    [J]. FRONTIERS IN GENETICS, 2022, 13
  • [48] THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
    Noma, Daisuke
    Sakamoto, Kazuhiro
    Ando, Kohei
    Amano, Shinya G.
    Sudo, Shigeto
    Goto, Hideto
    Yamakawa, Yasushi
    Tsubakihara, Motofumi
    Tsuboi, Masahiro
    Masuda, Munetaka
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1320 - S1320
  • [49] ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?
    Audigier-Vaiette, Clarisse
    Girard, Nicolas
    Cortot, Alexis B.
    Mennecier, Bertrand
    Debieuvre, Didier
    Planchard, David
    Zalcman, Gerard
    Moro-Sibilot, Denis
    Cadranel, Jacques
    Barlesi, Fabrice
    [J]. BULLETIN DU CANCER, 2014, 101 (09) : 823 - 831
  • [50] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    [J]. TUMORI JOURNAL, 2016, 102 : S46 - S49